Hepion Pharmaceuticals, Inc. 8-K

What Happened
Hepion Pharmaceuticals, Inc. announced that Chief Executive Officer Dr. Kaouthar Lbiati resigned for personal reasons effective March 16, 2026. On the same date the Board approved the appointment of Gary Stetz as interim Chief Executive Officer and director, named Vincent LoPriore as Executive Chairman, and appointed Sireesh Appajosyula and Chase LoPriore as directors. The company filed the Form 8-K reporting these changes on March 18, 2026.

Key Details

• Resignation: Dr. Kaouthar Lbiati resigned as CEO effective March 16, 2026.
• Interim CEO: Gary Stetz was appointed interim Chief Executive Officer and director, effective March 16, 2026.
• Board changes: Vincent LoPriore was appointed Executive Chairman; Sireesh Appajosyula and Chase LoPriore were appointed as directors, all effective March 16, 2026.
• Independence/relationships: The filing states there are no arrangements or understandings related to these selections and no family relationships between the new appointees and the company’s other directors or executive officers.

Why It Matters
This 8-K notifies investors of an immediate leadership and board change at Hepion, which updates who is running day-to-day operations (interim CEO) and who chairs the Board. The disclosure of no special arrangements or family ties is a governance detail investors can use when assessing board composition and oversight.